Phase 2 Sleep Disorders Trial, Recruiting NCT05814055 Sponsor: University of Florida Condition: Sleep Disorders
Back to Sleep Disorders

Phase 2 Sleep Disorders Trial, Recruiting

NCT05814055
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults between 21 and 75 years old
  • People who report smoking at least 5 cigarettes per day for the past year and want to quit at the time of screening
  • People whose breath test shows a carbon monoxide level above 8 ppm at the time of recruitment
  • People who are willing to take part and sign a consent form
  • People who have access to a working telephone
  • People who expect to remain in the trial's local area for the next 4 months
  • People who are not currently enrolled in any other stop-smoking programs
  • Women who could become pregnant must agree to use an accepted form of birth control during the study (accepted methods include birth control pills, a birth control shot, a birth control implant, an IUD, a diaphragm, or a cervical cap)
  • People who currently take a kava dietary supplement, or who have previously taken part in a kava-related trial, may still be considered eligible if all other criteria are met and at least 2 weeks have passed since their last use of kava

Who may not be able to join:

  • People who have had an active cancer diagnosis (other than a common type of non-serious skin cancer) within the past 2 years
  • People who have been diagnosed with liver problems or who have a history of liver disease
  • People whose blood test results for certain liver-related markers fall outside the normal range at the pre-screening stage (confirm with trial site)
  • People who are unable to avoid taking paracetamol (acetaminophen), drinking more than one alcoholic drink per day, or using other substances that may affect the liver
  • People who are pregnant, breastfeeding, planning to become pregnant during the study, or who are of childbearing age and unwilling to use adequate contraception
  • People whose responses to a standard set of suicide screening questions (called the Modified Ask Suicide Screening Questions) indicate current risk — specifically, anyone who answers "Yes" to questions 1 through 3, or who refuses to answer all questions. People who answered "Yes" to question 4 but whose most recent suicide attempt was more than 12 months before screening may still be considered eligible

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 6 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Ramzi Salloum, PhD, University of Florida

Phone: 352-294-4997

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
6 June 2024
Est. completion
31 January 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Subject Compliance with Intervention; Subject Compliance with Intervention

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov